SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for IFRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 16.14M
March 31, 2026 20.00M
September 30, 2025 21.12M
June 30, 2025 22.14M
March 31, 2025 22.73M
September 30, 2024 20.97M
June 30, 2024 20.86M
March 31, 2024 19.58M
December 31, 2023 17.98M
September 30, 2023 15.99M
June 30, 2023 14.24M
March 31, 2023 14.72M
December 31, 2022 15.77M
September 30, 2022 15.94M
June 30, 2022 16.83M
March 31, 2022 15.46M
December 31, 2021 14.17M
September 30, 2021 13.77M
June 30, 2021 11.13M
March 31, 2021 10.44M
December 31, 2020 9.624M
Date Value
September 30, 2020 10.14M
June 30, 2020 11.55M
March 31, 2020 13.08M
December 31, 2019 14.01M
September 30, 2019 14.71M
June 30, 2019 15.48M
March 31, 2019 15.14M
December 31, 2018 15.09M
September 30, 2018 13.34M
June 30, 2018 10.50M
March 31, 2018 7.301M
December 31, 2017 4.206M
September 30, 2017 1.863M
June 30, 2017 1.167M
March 31, 2017 0.8836M
December 31, 2016 0.537M
September 30, 2016 0.537M
June 30, 2016 0.537M
March 31, 2016 0.2514M
December 31, 2015 0.00

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
MediGene AG --
BioNTech SE 833.57M
Immatics NV 63.90M
Beam Therapeutics, Inc. 125.40M
Kymera Therapeutics, Inc. 75.75M